09/17/2014 - 12:27pm

The Ohio governor's office pushed for the firing of the executive director of the Ohio State Board of Pharmacy, according to a report released by the Associated Press Tuesday.

09/16/2014 - 5:19pm

With diabetes and other diseases at epidemic levels, the need for more pharmacies to step up and offer accessible, convenient patient screening for a variety of serious and even life-threatening conditions is clear, a panel of pharmacists asserted at the NACDS Total Store Expo “Convenient Care — Point of Care Testing in the Pharmacy” Insight Session in late August. So, too, is the opportunity to drive new business to the pharmacy through point-of-care testing services.

09/16/2014 - 12:55pm

The Food and Drug Administration on Tuesday announced approval for Movantik (naloxegol), a treatment for opioid-induced constipation in adults.

09/16/2014 - 12:09pm

Baxter International announced that the Food and Drug Adminsitration approved Rixubis [coagulation factor IX (recombinant)] for the treatment, control and prevention of bleeding episodes, as well as perioperative management, in children with hemophilia B. 

09/16/2014 - 9:28am

The Council for Responsible Nutrition on Monday praised the U.S. House of Representatives for its passage of the Designer Anabolic Steroid Control Act of 2014 (H.R. 4771), introduced by Reps. Joe Pitts, R-Pa., and Frank Pallone, D-N.J.

09/15/2014 - 3:15pm

Thanks to the Centers for Medicare and Medicaid Services’ Five-Star Quality Rating System, the diabetes community stands to play a significant role in how pharmacies think about their patients and their medication adherence programs. 

09/15/2014 - 10:14am

The Department of Justice announced Friday that it filed a motion to hold Bayer in civil contempt for violating a court order in the U.S. District Court for the District of New Jersey.

09/11/2014 - 1:40pm

Medivation and Astellas Pharma on Wednesday announced that the Food and Drug Administration approved a new use of Xtandi (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer.

09/11/2014 - 1:21pm

The Food and Drug Administration approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) as a chronic weight-management option.